NEW YORK (GenomeWeb News)– Myriad Genetics disclosed last week that Crescendo Bioscience recorded $27.3 million in revenues and a net loss of $41.1 million in 2013. Myriad acquired the autoimmune diagnostics company for $245 million in March. Crescendo spent $12.1 million on R&D last year and $26.4 million on SG&A. It ended the year with $3.1 million in cash and cash equivalents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.